Incidence of arterial, venous thrombosis high in patients with antibody-associated vasculitis
There appears to be a high incidence of arterial and venous thrombosis among patients with antineutrophil cytoplasmic antibody-associated vasculitis (AAV), particularly during the first year of diagnosis, according to a study.
A total of 204 patients with AAV were identified, with a median follow-up of 5.8 years (range, 1–10; 1,088 person-years [PY]) for surviving patients. The incidence of arterial thrombotic events (ATE) was 2.67/100 PY (1.56 for coronary events and 1.10 for ischaemic stroke), while that of venous thromboembolism (VTE) was 1.47/100 PY (0.83 for deep venous thrombosis [DVT] and 0.62 for pulmonary embolism [PE] with/without DVT).
Multivariate analysis revealed that the only independent predictors of ATE were prior ischaemic heart disease (IHD) and advance age. There remained an increased incidence of ATE at 2.32/100 PY (1.26 for coronary events and 1.06 for ischaemic stroke) among patients without prior IHD or stroke. ATE, but not VTE, independently predicted all-cause mortality.
The highest event rates for both ATE and VTE were recorded in the first year after diagnosis of AAV, which remained above the population incidence during the 10-year follow-up period. Compared to reported rates for the UK population, event rates were 15-times higher for coronary events, 11-times higher for incident stroke and 20-times higher for VTE in this cohort of AAV patients.
This retrospective cohort study aimed to determine the incidence of ATE (coronary events or ischaemic stroke) and VTE (PE or DVT) in patients diagnosed with AAV between 2005 and 2014.